Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 16,142 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: high dose melphalan and autologous bone marrow transplantation; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1984 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: TNFerade™; Drug
Lead sponsor: GenVec; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Keloid
Interventions: Avotermin (Juvista), Placebo; Drug
Lead sponsor: Renovo; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acne Rosacea
Interventions: ACCU-D1, Vehicle; Drug
Lead sponsor: Accuitis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Louisville, Kentucky • Austin, Texas

Conditions: Metastatic Breast Cancer, Brain Metastases
Interventions: Pembrolizumab; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Years to 90 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 3
States / cities: New York, New York

Conditions: Systemic Lupus Erythematosus, Sjogren's Syndrome
Interventions: BioCLIA Ro60; Device
Lead sponsor: HOB Biotech Group; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Irvine, California

Conditions: Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
Interventions: Provider determined; Other
Lead sponsor: CureOne; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Idaho Falls, Idaho

Conditions: Wounds and Injuries
Interventions: Allevyn Life, Foam dressing with an integrated adhesive border; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Tustin, California • Wichita, Kansas • McAllen, Texas

Conditions: Breast Cancer, Gynecologic Cancer
Interventions: Psychosexual Educational Partner Program (PEPP); Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions: ENV-101 (taladegib); Drug
Lead sponsor: Endeavor Biomedicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more

Conditions: Melanoma
Interventions: DC Vaccine + IFN, AdVTMM2/DC Vaccination; Biological
Lead sponsor: Lisa H. Butterfield, Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pediculosis
Interventions: Group A - Low-Dose Ha44 0.37% w/w, Group B - High Dose Ha44 Gel 0.74% w/w, Group C - Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 2 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Dinuba, California • Los Angeles, California

Conditions: Hereditary Angioedema
Interventions: Navenibart; Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more

Conditions: Breast Cancer
Interventions: DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 4
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Rochester, Minnesota + 1 more

Conditions: Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
Interventions: Palbociclib, Bazedoxifene; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Immune Thrombocytopenic Purpura
Interventions: Fostamatinib disodium, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 13
States / cities: Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 10 more

Conditions: Psoriasis
Interventions: Placebo, Adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more

Conditions: Mucopolysaccharidosis I
Interventions: No Intervention; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Breast Cancer, DCIS
Interventions: Meditation; Other
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Health coach-led, online support program for people living with lupus; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma
Interventions: AMG 232, Trametinib, Dabrafenib; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 2 more

Conditions: Sly Syndrome, MPS VII, Mucopolysaccharidosis, Mucopolysaccharidosis VII
Interventions: UX003; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Day to 5 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New York, New York • Salt Lake City, Utah

Conditions: Generalized Epidermolysis Bullosa Simplex
Interventions: AC-203, Vehicle; Drug
Lead sponsor: TWi Biotechnology, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Skin Cancer
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer

TNFerade™ Biologic Plus Radiation for Metastatic Melanoma

Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Clinical Performance of BioCLIA Ro60

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

Managing Wounds With Allevyn Life in a Home Health Care Environment

Developing a Psychosexual Educational Partners Program: PEPP A Feasibility Study

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Multiple Antigen-Engineered DC Vaccine for Melanoma

An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation

A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema

DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

Long Term Follow-Up for RGX-111

Perioperative Mindfulness Proposal

Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Patient Satisfaction in Cutaneous Surgery